Bufalin/Huachansu / β-catenin/ZEB1 Cancer Research Results

BF, Bufalin/Huachansu: Click to Expand ⟱
Features:
Bufalin/Huachansu is a component from Chinese toad venom. Bufalin is classified as a cardiac glycoside, specifically a type of bufadienolide.

Pathways:
-release of cytochrome c and subsequent activation of caspases
-enhance the expression of death receptors
-inhibit the PI3K/Akt/mTOR
-modulate the MAPK/ERK pathway
-inhibit NF-κB signaling
-induce cell cycle arrest at different checkpoints (commonly G0/G1 or G2/M)
-elevate intracellular ROS levels
-interfere with the Wnt/β-catenin signaling pathway
-modulate autophagy, a process that can either promote cell survival or lead to cell death
-Stabilization or activation of p53

Bufalin — Bufalin is a steroidal cardiotonic toxin and anticancer lead compound, classically isolated from toad venom (ChanSu / Huachansu) and belonging to the bufadienolide subclass of cardiac glycosides. It is commonly abbreviated BF. In cancer research, bufalin is best understood as a pleiotropic signaling disruptor whose most central pharmacology is linked to Na+/K+-ATPase engagement, with downstream effects on survival signaling, mitochondrial death pathways, redox stress, stemness, invasion, and therapy resistance.

Primary mechanisms (ranked):

  1. Na+/K+-ATPase targeting with disruption of pump-linked oncogenic signaling and, in some models, α1-subunit destabilization/degradation.
  2. Mitochondria-linked apoptosis with cytochrome c release, caspase activation, and loss of survival signaling.
  3. Suppression of PI3K/Akt/mTOR and related pro-survival nodes, with context-dependent effects on ERK, NF-κB, and STAT3-linked programs.
  4. ROS elevation with stress-kinase activation (especially JNK/p38) and redox-dependent death signaling; this is important but usually downstream/secondary rather than the first initiating event.
  5. Cell-cycle arrest and mitotic disruption, including Aurora kinase-related effects in some tumor models.
  6. Inhibition of stemness, EMT, migration, invasion, angiogenesis, and drug-resistance phenotypes, including Wnt/β-catenin- and YAP-associated programs in selected cancers.
  7. Autophagy modulation, which can be cytoprotective or cytotoxic depending on model and schedule.

Bioavailability / PK relevance: Translation is constrained by poor water solubility, low/variable bioavailability of bufadienolides, short apparent plasma persistence in human Huachansu infusion studies, and a narrow therapeutic window typical of cardiac glycosides. CYP3A-mediated metabolism and CYP3A4 inhibition/time-dependent inactivation raise drug-interaction concern. Delivery optimization by nanoparticles, prodrugs, and formulation engineering is mechanistically relevant, not merely cosmetic.

In-vitro vs systemic exposure relevance: Concentration-driven. Many mechanistic cancer studies report activity in low-nanomolar to submicromolar ranges, which is closer to plausibility than for many phytochemicals; however, human plasma bufalin levels reported during Huachansu infusion were only low ng/mL and showed little accumulation, so many higher in-vitro conditions likely exceed sustained clinically achieved free exposure. Any interpretation should therefore prioritize low-nanomolar findings and delivery-enabled tumor exposure rather than high-concentration cell-culture effects.

Clinical evidence status: Preclinical to small-human evidence only. There is substantial in-vitro and animal evidence, plus early Huachansu clinical studies in China and a phase I/II development path, but no convincing randomized evidence that bufalin-containing therapy improves major cancer outcomes. Current status is best described as experimental / adjunct-oriented rather than established anticancer therapy.

Mechanistic translation matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Na+/K+-ATPase signalosome ↓ pump-linked oncogenic signaling; ↓ proliferation; apoptosis trigger ↓ ubiquitous pump function; cardiotoxicity risk P-R Upstream target engagement Most central mechanism. Bufalin behaves as a cardiac glycoside/bufadienolide with strong relevance to ATP1A1-linked signaling and tumor vulnerability, but normal-tissue exposure limits selectivity.
2 Mitochondria and intrinsic apoptosis ↑ cytochrome c release; ↑ caspases; ↑ mitochondrial dysfunction ↔ to ↓ tolerance window R-G Cell death induction Robust across many tumor models and commonly downstream of Na+/K+-ATPase disruption, ROS stress, and survival-pathway collapse.
3 PI3K Akt mTOR survival axis ↓ ↔ to ↓ R-G Anti-survival signaling One of the most repeatedly reported downstream axes. Often linked to apoptosis sensitization, growth arrest, and resistance reversal.
4 NF-κB inflammatory survival signaling ↓ ↔ to ↓ R-G Reduced survival and inflammatory tone Usually a secondary convergence node rather than the first molecular hit.
5 Mitochondrial ROS increase ↑ (dose-dependent) ↑ toxicity risk R Stress amplification Mechanistically important in several models, especially where JNK/p38 activation and autophagy-mediated death are observed. Not universal as the dominant initiating event.
6 JNK p38 stress kinase axis ↑ ↔ R-G Pro-apoptotic stress signaling Often coupled to ROS elevation and mitochondrial injury.
7 ERK MAPK signaling ↓ or ↔ (context-dependent) ↔ R-G Growth signaling modulation Reported direction varies by model; best treated as context-dependent rather than universally suppressed.
8 Cell-cycle and mitotic machinery ↑ G0/G1 or G2/M arrest; ↓ Aurora activation ↔ to ↓ proliferative tissues G Cytostasis and mitotic disruption Relevant in multiple cancers; checkpoint phenotype varies by model.
9 Wnt β-catenin stemness axis ↓ stemness; ↓ EMT; ↓ invasion ↔ G Anti-metastatic differentiation pressure Important in selected resistant and stem-like states rather than universally core.
10 Autophagy program ↑ or ↓ (context-dependent) ↔ R-G Death modulator Can either support survival or contribute to death. Interpretation must stay model-specific.
11 Chemosensitization and resistance reversal ↑ sensitivity ↔ G Adjunct potential Preclinical evidence is strong enough to keep this high in translational interest, but human confirmation is still weak.
12 Clinical Translation Constraint Exposure limited Systemic toxicity relevant G Therapeutic window constraint Poor solubility, formulation dependence, short plasma persistence, CYP3A liability, and cardiac-glycoside toxicity remain the main barriers to direct clinical deployment.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
β-catenin/ZEB1, β-catenin/ZEB1: Click to Expand ⟱
Source: HalifaxProj (inactivate)
Type:
β-catenin and ZEB1 are two important proteins that play significant roles in cancer biology, particularly in the processes of cell adhesion, epithelial-mesenchymal transition (EMT), and tumor progression.
β-catenin is a key component of the Wnt signaling pathway, which is crucial for cell proliferation, differentiation, and survival. It also plays a role in cell-cell adhesion by linking cadherins to the actin cytoskeleton.
Role in Cancer: ZEB1 is often upregulated in cancer and is associated with increased invasiveness and metastasis. It can repress epithelial markers (like E-cadherin) and promote mesenchymal markers (like N-cadherin and vimentin), facilitating the transition to a more aggressive cancer phenotype.

(MMP)-2 and MMP-9, which are the down-stream targets of β-catenin and play a crucial role in cancer cell metastasis.
Scientific Papers found: Click to Expand⟱
5721- BF,    Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway
- in-vitro, BC, NA
CSCs↓, TumCCA↑, cMyc↓, cycD1/CCND1↓, CDK4↓, MMP↓, Casp↑, CD133↓, CD44↓, ALDH1A1↓, Nanog↓, OCT4↓, SOX2↓, Wnt↓, β-catenin/ZEB1↓, EGFR↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Casp↑, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   CD133↓, 1,   CD44↓, 1,   CSCs↓, 1,   Nanog↓, 1,   OCT4↓, 1,   SOX2↓, 1,   Wnt↓, 1,  

Migration ⓘ

β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: β-catenin/ZEB1, β-catenin/ZEB1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:49  Target#:342  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page